Chief Executive Officer · ARS Pharmaceuticals, Inc. (SPRY)

Laura Shawver

A named executive officer of ARS Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$821,500

Salary $530,000Stock awards $0

FY2020: $13,819,725

1st of 3 named executive officers at ARS Pharmaceuticals by FY2021 total.

3 named officers on file for ARS Pharmaceuticals, FY2021

Laura Shawver’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • SPRY’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARS Pharmaceuticals’s whole pay program stands against its peers

  • ARS Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Laura Shawver’s full pay file as a PDF — free

More than this page: up to 10 years of Laura’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Laura Shawver compensation by year

ARS Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as ARS Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$324,811$530,000
Bonus$0$0
Stock awards$0$0
Option awards$13,166,894$0
Non-equity incentive$283,545$291,500
Pension and deferred compensation$0$0
All other$44,475$0
Total$13,819,725$821,500

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127830, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-22-127830. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

$13.8M
$822K
FY20
FY21
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option152,757—$6.65
Option421,974—$21.00

Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

36 Form 4 lines since the FY2021 proxy (filed April 28, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-24Grant or award derivative—30,000$0.0030,000
2025-06-25Grant or award derivative—30,000$0.0030,000
2025-04-07Exercise or conversion10b5-122,509$4.85232,855
2025-04-07Sale10b5-150,002$12.30210,346
2025-04-07Exercise or conversion derivative10b5-122,509$0.0051,555
2025-04-07Exercise or conversion derivative10b5-127,493$0.0024,062
2025-04-07Exercise or conversion10b5-127,493$4.85260,348
2025-03-06Exercise or conversion10b5-149,600$4.85259,946

The 8 most recent of 36 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ARS Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Laura Shawver · this pageChief Executive Officer$821,500
Valerie OdegardPresident and Chief Scientific Officer$633,600
Jonathan PiazzaChief Financial Officer$612,000

Board service

ARS Pharmaceuticals board · FY2023–FY2025
Director compensation in US dollars, as ARS Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$49,792—$367,959$0$417,751
FY2024$40,000—$232,932$0$272,932
FY2023$40,000—$198,800$0$238,800

Each year as the company reported it in ARS Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: ARS Pharmaceuticals pays directors a $50,000 cash retainer. As stated in ARS Pharmaceuticals's FY2025 proxy.

Committees

Compensation

The full ARS Pharmaceuticals compensation record

free company brief

This page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARS Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Laura Shawver's compensation dossier · One-time report. No refunds.